Vision, values, and leadership

About

Cognoa is a consumer healthcare company that’s changing how parents assess and support their child’s development. Already one of the largest screeners of children's development, Cognoa gives parents peace of mind by identifying where a child is on track and what parents can do to help the child improve.

Cognoa’s Harvard-developed evaluation is validated using data from over 10,000 children. It is based on more than 5 years of clinical research and validation studies led by Dennis Wall, PhD at prominent institutions including Harvard Medical School and Stanford Medical School.

Leadership Team

Brent Vaughan
CEO

Brent has over 20 years of experience in personalized medicine, diagnostics, and empowering patients to take more control of their health. He was most recently COO of WellnessFX, where he built a consumer mobile health and diagnostics platform that provided its members with direct access to and control over their diagnostic information.

Clara Lajonchere
Scientific Advisor

Dr. Lajonchere is an academic researcher and leading expert on autism spectrum disorders who has worked in the field of psychiatric genetics for over 25 years. She has held the positions of VP of Clinical Programs at Autism Speaks, Research Assistant Professor of Biomedical Engineering, Clinical Assistant Professor of Pediatrics at USC, and Chief Science Officer at Cognoa. She is currently the Deputy Director for the Institute for Precision Health at UCLA and continues to serve on Cognoa’s scientific advisory board.

Dennis Wall
Scientific Founder

Dr. Wall is the scientific founder of Cognoa who developed the company's proprietary child behavior assessments and data science as a researcher at Harvard Medical School. Dr. Wall currently leads research in analytical medicine and pediatrics at the Wall Lab at Stanford Medical School, where he is on faculty.

Investors

The lead investor in Cognoa is Morningside Ventures. Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific and in Mainland China. Morningside was one of the earliest institutional investors in China. Its offices are located in Boston, Beijing, Shanghai and Hong Kong.